Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IBI-110 by Innovent Biologics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
IBI-110 by Innovent Biologics for Gastric Cancer: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
IBI-110 by Innovent Biologics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...
IBI-110 by Innovent Biologics for Hepatocellular Carcinoma: Likelihood of Approval
IBI-110 is under clinical development by Innovent Biologics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...